Low-Dose Pantoprazole (20mg) is Effective for Treatment of Mild Reflux Oesophagitis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-12

AUTHORS

Ector J. Ramírez-Barba, Miguel Dibildox, Fernando Bernal, Miguel Abdo, Alfonso Moguel, Luis-Humberto López, Renate Fischer

ABSTRACT

Aim: Reflux of gastric acid into the oesophagus plays an important role in the development of gastro-oesophageal reflux disease (GORD). The aim of this study was to compare the efficacy and tolerability of pantoprazole 20 mg/day with ranitidine 300 mg/day in patients with mild GORD.Materials and Methods: Patients (n = 273, intention-to-treat population) with endoscopically confirmed mild reflux oesophagitis (Savary-Miller stage I) were enrolled in this randomised (2:1), double-blind, parallel group study in 32 centres in Mexico. Patients received pantoprazole 20mg once daily or ranitidine 150mg twice daily. Endoscopy was performed after 4 weeks of therapy; patients with endoscopic evidence of oesophagitis were treated for a further 4 weeks. Tolerability of the study medications was assessed by comparing the frequency of adverse events and results of clinical laboratory tests during the study.Results: The per-protocol population consisted of 263 patients. After 4 weeks of treatment the healing rates were 89% (158/177) with pantoprazole and 76% (65/86) with ranitidine (p = 0.003, per-protocol population). After 8 weeks of therapy, the cumulative healing rates were 96% (169/177) and 88% (76/86), respectively (p = 0.03, per-protocol population). After 4 weeks of treatment, relief from heartburn was significantly superior for patients treated with pantoprazole than for those treated with ranitidine (p = 0.003). Both study medications were well tolerated.Conclusions: Compared with ranitidine (150mg twice daily), pantoprazole (20mg once daily) produced significantly superior healing rates. Low-dose pantoprazole 20mg was well tolerated. More... »

PAGES

445-451

References to SciGraph publications

  • 1998-09. Proton Pump Inhibitors in DRUGS
  • 1996-03. Pantoprazole in DRUGS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00044011-199918060-00003

    DOI

    http://dx.doi.org/10.2165/00044011-199918060-00003

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1039037355


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Facultad de Medicina, Universidad de Guanajuato, 20 de enero No 929, 36000, Leon, Guanajuato, M\u00e9xico", 
              "id": "http://www.grid.ac/institutes/grid.412891.7", 
              "name": [
                "Facultad de Medicina, Universidad de Guanajuato, 20 de enero No 929, 36000, Leon, Guanajuato, M\u00e9xico"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ram\u00edrez-Barba", 
            "givenName": "Ector J.", 
            "id": "sg:person.01072316656.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072316656.41"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Investigati\u00f3n Cl\u00ednica, Byk Gulden, Mexico City, Mexico", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Investigati\u00f3n Cl\u00ednica, Byk Gulden, Mexico City, Mexico"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dibildox", 
            "givenName": "Miguel", 
            "id": "sg:person.01047715072.68", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047715072.68"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Hospital General de Mexico, Mexico City, Mexico", 
              "id": "http://www.grid.ac/institutes/grid.414716.1", 
              "name": [
                "Hospital General de Mexico, Mexico City, Mexico"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bernal", 
            "givenName": "Fernando", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Hospital General de Mexico, Mexico City, Mexico", 
              "id": "http://www.grid.ac/institutes/grid.414716.1", 
              "name": [
                "Hospital General de Mexico, Mexico City, Mexico"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Abdo", 
            "givenName": "Miguel", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Investigati\u00f3n Cl\u00ednica, Novartis Mexicana, Mexico City, Mexico", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Investigati\u00f3n Cl\u00ednica, Novartis Mexicana, Mexico City, Mexico"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Moguel", 
            "givenName": "Alfonso", 
            "id": "sg:person.01157777132.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157777132.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Investigati\u00f3n Cl\u00ednica, Byk Gulden, Mexico City, Mexico", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Investigati\u00f3n Cl\u00ednica, Byk Gulden, Mexico City, Mexico"
              ], 
              "type": "Organization"
            }, 
            "familyName": "L\u00f3pez", 
            "givenName": "Luis-Humberto", 
            "id": "sg:person.01235761070.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235761070.11"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Byk Gulden Pharmaceuticals, Konstanz, Germany", 
              "id": "http://www.grid.ac/institutes/grid.418522.8", 
              "name": [
                "Byk Gulden Pharmaceuticals, Konstanz, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fischer", 
            "givenName": "Renate", 
            "id": "sg:person.01075762560.82", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075762560.82"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2165/00003495-199651030-00012", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019374600", 
              "https://doi.org/10.2165/00003495-199651030-00012"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-199856030-00002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002711564", 
              "https://doi.org/10.2165/00003495-199856030-00002"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1999-12", 
        "datePublishedReg": "1999-12-01", 
        "description": "Aim: Reflux of gastric acid into the oesophagus plays an important role in the development of gastro-oesophageal reflux disease (GORD). The aim of this study was to compare the efficacy and tolerability of pantoprazole 20 mg/day with ranitidine 300 mg/day in patients with mild GORD.Materials and Methods: Patients (n = 273, intention-to-treat population) with endoscopically confirmed mild reflux oesophagitis (Savary-Miller stage I) were enrolled in this randomised (2:1), double-blind, parallel group study in 32 centres in Mexico. Patients received pantoprazole 20mg once daily or ranitidine 150mg twice daily. Endoscopy was performed after 4 weeks of therapy; patients with endoscopic evidence of oesophagitis were treated for a further 4 weeks. Tolerability of the study medications was assessed by comparing the frequency of adverse events and results of clinical laboratory tests during the study.Results: The per-protocol population consisted of 263 patients. After 4 weeks of treatment the healing rates were 89% (158/177) with pantoprazole and 76% (65/86) with ranitidine (p = 0.003, per-protocol population). After 8 weeks of therapy, the cumulative healing rates were 96% (169/177) and 88% (76/86), respectively (p = 0.03, per-protocol population). After 4 weeks of treatment, relief from heartburn was significantly superior for patients treated with pantoprazole than for those treated with ranitidine (p = 0.003). Both study medications were well tolerated.Conclusions: Compared with ranitidine (150mg twice daily), pantoprazole (20mg once daily) produced significantly superior healing rates. Low-dose pantoprazole 20mg was well tolerated.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00044011-199918060-00003", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1100199", 
            "issn": [
              "1173-2563", 
              "1179-1918"
            ], 
            "name": "Clinical Drug Investigation", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "18"
          }
        ], 
        "keywords": [
          "gastro-oesophageal reflux disease", 
          "mild reflux oesophagitis", 
          "weeks of therapy", 
          "weeks of treatment", 
          "healing rate", 
          "study medication", 
          "reflux oesophagitis", 
          "mild gastro-oesophageal reflux disease", 
          "Low-dose pantoprazole", 
          "superior healing rates", 
          "parallel group study", 
          "cumulative healing rates", 
          "clinical laboratory tests", 
          "endoscopic evidence", 
          "protocol population", 
          "reflux disease", 
          "adverse events", 
          "gastric acid", 
          "patients", 
          "ranitidine", 
          "oesophagitis", 
          "pantoprazole", 
          "group study", 
          "weeks", 
          "tolerability", 
          "medications", 
          "therapy", 
          "treatment", 
          "laboratory tests", 
          "days", 
          "heartburn", 
          "esophagus", 
          "endoscopy", 
          "reflux", 
          "disease", 
          "important role", 
          "daily", 
          "study", 
          "efficacy", 
          "rate", 
          "relief", 
          "aim", 
          "population", 
          "evidence", 
          "role", 
          "center", 
          "events", 
          "test", 
          "frequency", 
          "acid", 
          "development", 
          "results", 
          "method", 
          "materials", 
          "Mexico", 
          "Dose Pantoprazole"
        ], 
        "name": "Low-Dose Pantoprazole (20mg) is Effective for Treatment of Mild Reflux Oesophagitis", 
        "pagination": "445-451", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1039037355"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00044011-199918060-00003"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00044011-199918060-00003", 
          "https://app.dimensions.ai/details/publication/pub.1039037355"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-11-01T18:04", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_335.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00044011-199918060-00003"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00044011-199918060-00003'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00044011-199918060-00003'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00044011-199918060-00003'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00044011-199918060-00003'


     

    This table displays all metadata directly associated to this object as RDF triples.

    173 TRIPLES      22 PREDICATES      84 URIs      74 LITERALS      6 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00044011-199918060-00003 schema:about anzsrc-for:11
    2 anzsrc-for:1103
    3 schema:author N2b30ed9603584695b7eddbce2b2c3e40
    4 schema:citation sg:pub.10.2165/00003495-199651030-00012
    5 sg:pub.10.2165/00003495-199856030-00002
    6 schema:datePublished 1999-12
    7 schema:datePublishedReg 1999-12-01
    8 schema:description Aim: Reflux of gastric acid into the oesophagus plays an important role in the development of gastro-oesophageal reflux disease (GORD). The aim of this study was to compare the efficacy and tolerability of pantoprazole 20 mg/day with ranitidine 300 mg/day in patients with mild GORD.Materials and Methods: Patients (n = 273, intention-to-treat population) with endoscopically confirmed mild reflux oesophagitis (Savary-Miller stage I) were enrolled in this randomised (2:1), double-blind, parallel group study in 32 centres in Mexico. Patients received pantoprazole 20mg once daily or ranitidine 150mg twice daily. Endoscopy was performed after 4 weeks of therapy; patients with endoscopic evidence of oesophagitis were treated for a further 4 weeks. Tolerability of the study medications was assessed by comparing the frequency of adverse events and results of clinical laboratory tests during the study.Results: The per-protocol population consisted of 263 patients. After 4 weeks of treatment the healing rates were 89% (158/177) with pantoprazole and 76% (65/86) with ranitidine (p = 0.003, per-protocol population). After 8 weeks of therapy, the cumulative healing rates were 96% (169/177) and 88% (76/86), respectively (p = 0.03, per-protocol population). After 4 weeks of treatment, relief from heartburn was significantly superior for patients treated with pantoprazole than for those treated with ranitidine (p = 0.003). Both study medications were well tolerated.Conclusions: Compared with ranitidine (150mg twice daily), pantoprazole (20mg once daily) produced significantly superior healing rates. Low-dose pantoprazole 20mg was well tolerated.
    9 schema:genre article
    10 schema:inLanguage en
    11 schema:isAccessibleForFree false
    12 schema:isPartOf N0a83ba56a0754ab18724ddbc7786494f
    13 N37129ba3cabc41299b561a7f2f113b51
    14 sg:journal.1100199
    15 schema:keywords Dose Pantoprazole
    16 Low-dose pantoprazole
    17 Mexico
    18 acid
    19 adverse events
    20 aim
    21 center
    22 clinical laboratory tests
    23 cumulative healing rates
    24 daily
    25 days
    26 development
    27 disease
    28 efficacy
    29 endoscopic evidence
    30 endoscopy
    31 esophagus
    32 events
    33 evidence
    34 frequency
    35 gastric acid
    36 gastro-oesophageal reflux disease
    37 group study
    38 healing rate
    39 heartburn
    40 important role
    41 laboratory tests
    42 materials
    43 medications
    44 method
    45 mild gastro-oesophageal reflux disease
    46 mild reflux oesophagitis
    47 oesophagitis
    48 pantoprazole
    49 parallel group study
    50 patients
    51 population
    52 protocol population
    53 ranitidine
    54 rate
    55 reflux
    56 reflux disease
    57 reflux oesophagitis
    58 relief
    59 results
    60 role
    61 study
    62 study medication
    63 superior healing rates
    64 test
    65 therapy
    66 tolerability
    67 treatment
    68 weeks
    69 weeks of therapy
    70 weeks of treatment
    71 schema:name Low-Dose Pantoprazole (20mg) is Effective for Treatment of Mild Reflux Oesophagitis
    72 schema:pagination 445-451
    73 schema:productId Na8dff8184fd3433a95c7be65c88ed9cc
    74 Nf6629b6d249444eb8274c93942e77d8b
    75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039037355
    76 https://doi.org/10.2165/00044011-199918060-00003
    77 schema:sdDatePublished 2021-11-01T18:04
    78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    79 schema:sdPublisher N92b20014717a411bb944713e41b705bd
    80 schema:url https://doi.org/10.2165/00044011-199918060-00003
    81 sgo:license sg:explorer/license/
    82 sgo:sdDataset articles
    83 rdf:type schema:ScholarlyArticle
    84 N0a83ba56a0754ab18724ddbc7786494f schema:volumeNumber 18
    85 rdf:type schema:PublicationVolume
    86 N1fc8e85696784897a4ec60260ebd77c0 rdf:first sg:person.01075762560.82
    87 rdf:rest rdf:nil
    88 N2b30ed9603584695b7eddbce2b2c3e40 rdf:first sg:person.01072316656.41
    89 rdf:rest N3ed2fa94eaa44762a02131c830ab166b
    90 N2cc646bd797c48b7ab457c51f032b87d schema:affiliation grid-institutes:grid.414716.1
    91 schema:familyName Bernal
    92 schema:givenName Fernando
    93 rdf:type schema:Person
    94 N2ed0aa7ce6784c5f8e01fac55f332963 schema:affiliation grid-institutes:grid.414716.1
    95 schema:familyName Abdo
    96 schema:givenName Miguel
    97 rdf:type schema:Person
    98 N37129ba3cabc41299b561a7f2f113b51 schema:issueNumber 6
    99 rdf:type schema:PublicationIssue
    100 N3ed2fa94eaa44762a02131c830ab166b rdf:first sg:person.01047715072.68
    101 rdf:rest Nc4e28571137a46deb1fa3234f526bf21
    102 N4f89d07927554880b71dc7fad1c3a2d7 rdf:first sg:person.01157777132.34
    103 rdf:rest N91659fdeaf924f69a8f9652dc2c07fd9
    104 N91659fdeaf924f69a8f9652dc2c07fd9 rdf:first sg:person.01235761070.11
    105 rdf:rest N1fc8e85696784897a4ec60260ebd77c0
    106 N92b20014717a411bb944713e41b705bd schema:name Springer Nature - SN SciGraph project
    107 rdf:type schema:Organization
    108 Na8dff8184fd3433a95c7be65c88ed9cc schema:name doi
    109 schema:value 10.2165/00044011-199918060-00003
    110 rdf:type schema:PropertyValue
    111 Nbd2a2d139cc945e8a55d78ec8d5de6c0 rdf:first N2ed0aa7ce6784c5f8e01fac55f332963
    112 rdf:rest N4f89d07927554880b71dc7fad1c3a2d7
    113 Nc4e28571137a46deb1fa3234f526bf21 rdf:first N2cc646bd797c48b7ab457c51f032b87d
    114 rdf:rest Nbd2a2d139cc945e8a55d78ec8d5de6c0
    115 Nf6629b6d249444eb8274c93942e77d8b schema:name dimensions_id
    116 schema:value pub.1039037355
    117 rdf:type schema:PropertyValue
    118 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    119 schema:name Medical and Health Sciences
    120 rdf:type schema:DefinedTerm
    121 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    122 schema:name Clinical Sciences
    123 rdf:type schema:DefinedTerm
    124 sg:journal.1100199 schema:issn 1173-2563
    125 1179-1918
    126 schema:name Clinical Drug Investigation
    127 schema:publisher Springer Nature
    128 rdf:type schema:Periodical
    129 sg:person.01047715072.68 schema:affiliation grid-institutes:None
    130 schema:familyName Dibildox
    131 schema:givenName Miguel
    132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047715072.68
    133 rdf:type schema:Person
    134 sg:person.01072316656.41 schema:affiliation grid-institutes:grid.412891.7
    135 schema:familyName Ramírez-Barba
    136 schema:givenName Ector J.
    137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072316656.41
    138 rdf:type schema:Person
    139 sg:person.01075762560.82 schema:affiliation grid-institutes:grid.418522.8
    140 schema:familyName Fischer
    141 schema:givenName Renate
    142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075762560.82
    143 rdf:type schema:Person
    144 sg:person.01157777132.34 schema:affiliation grid-institutes:None
    145 schema:familyName Moguel
    146 schema:givenName Alfonso
    147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157777132.34
    148 rdf:type schema:Person
    149 sg:person.01235761070.11 schema:affiliation grid-institutes:None
    150 schema:familyName López
    151 schema:givenName Luis-Humberto
    152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235761070.11
    153 rdf:type schema:Person
    154 sg:pub.10.2165/00003495-199651030-00012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019374600
    155 https://doi.org/10.2165/00003495-199651030-00012
    156 rdf:type schema:CreativeWork
    157 sg:pub.10.2165/00003495-199856030-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002711564
    158 https://doi.org/10.2165/00003495-199856030-00002
    159 rdf:type schema:CreativeWork
    160 grid-institutes:None schema:alternateName Investigatión Clínica, Byk Gulden, Mexico City, Mexico
    161 Investigatión Clínica, Novartis Mexicana, Mexico City, Mexico
    162 schema:name Investigatión Clínica, Byk Gulden, Mexico City, Mexico
    163 Investigatión Clínica, Novartis Mexicana, Mexico City, Mexico
    164 rdf:type schema:Organization
    165 grid-institutes:grid.412891.7 schema:alternateName Facultad de Medicina, Universidad de Guanajuato, 20 de enero No 929, 36000, Leon, Guanajuato, México
    166 schema:name Facultad de Medicina, Universidad de Guanajuato, 20 de enero No 929, 36000, Leon, Guanajuato, México
    167 rdf:type schema:Organization
    168 grid-institutes:grid.414716.1 schema:alternateName Hospital General de Mexico, Mexico City, Mexico
    169 schema:name Hospital General de Mexico, Mexico City, Mexico
    170 rdf:type schema:Organization
    171 grid-institutes:grid.418522.8 schema:alternateName Byk Gulden Pharmaceuticals, Konstanz, Germany
    172 schema:name Byk Gulden Pharmaceuticals, Konstanz, Germany
    173 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...